Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

We sought to assess the relationship between the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering and rates of elevated liver enzymes, rhabdomyolysis, and cancer. Although it is often assumed that statin-associated adverse events are proportional to LDL-C reduction, that assumption...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2007-07, Vol.50 (5), p.409
Main Authors: Alsheikh-Ali, Alawi A, Maddukuri, Prasad V, Han, Hui, Karas, Richard H
Format: Article
Language:English
Subjects:
Cancer
Cardiology
Chemical and Drug Induced Liver Injury
Cholesterol
Cholesterol, LDL - drug effects
Cholesterol, LDL - metabolism
Dose-Response Relationship, Drug
Enzymes
Fatty Acids, Monounsaturated - adverse effects
Hematology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hypercholesterolemia - drug therapy
Hypercholesterolemia - metabolism
Indoles - adverse effects
Lipids
Liver
Liver Diseases - enzymology
Lovastatin - adverse effects
Melanoma
Neoplasms - chemically induced
Neoplasms - epidemiology
Pravastatin - adverse effects
Rhabdomyolysis - chemically induced
Simvastatin - adverse effects
Statins
Statistical methods
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We sought to assess the relationship between the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering and rates of elevated liver enzymes, rhabdomyolysis, and cancer. Although it is often assumed that statin-associated adverse events are proportional to LDL-C reduction, that assumption has not been validated. Adverse events reported in large prospective randomized statin trials were evaluated. The relationship between LDL-C reduction and rates of elevated liver enzymes, rhabdomyolysis, and cancer per 100,000 person-years was assessed using weighted univariate regression. In 23 statin treatment arms with 309,506 person-years of follow-up, there was no significant relationship between percent LDL-C lowering and rates of elevated liver enzymes (R2
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2007.02.073